KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study.

Shuang Huang, Feng Liu, Song Qu, Lisha Chen, Ping Zhou, Shenhong Qu, Xiaohong Ai, Yong Chen, Meilian Liu, Rensheng Wang, Kelvin Kw Chan, Peng Zhang, Chunhong Hu, Jiyu Wen, Jian Zhang, Qin Lin, Xiaojiang Li, Kangsheng Gu, Li Xiang, Dongxia Wang, Jingao Li, Daren Lin, Desheng Hu, Jianwu Ding, Siyang Wang, Xiaoming Huang, Lin Wang, Feng Jin, David G Pfister, Milena Perez Mak, Pedro Rafael Martins de Marchi, Yi Jiang, Haihua Yang, Xiaoye Hu, Tianrun Liu, Dehua Wu, Aditya Shreenivas, Thiago Bueno de Oliveira, Carlos Eduardo Baston Silva, Gustavo Vasconcelos Alves, Xianming Li, Zhifang Yao, Dongmei Lu, Mingxiu Hu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Xiaozhong Chen, Chaosu Hu, Tingting Xu

Signal Transduct Target Ther 11(1) 126

PMID41946687
PMCIDPMC13056984
DOI10.1038/s41392-026-02645-0
发表日期2026-04-07
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

In this phase 3 trial, penpulimab combined with chemotherapy was assessed against a regimen of placebo plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). 291 patients were randomised and allocated in a 1:1 ratio in order to receive penpulimab (n = 144; 200 mg) or placebo (n = 147; 200 mg), plus chemotherapy (cisplatin/carboplatin and gemcitabine) every 3 weeks. Patients followed by maintenance therapy with penpulimab or placebo after 6 cycles. The primary endpoint of this study was progression-free survival (PFS) according to RECIST v1.1, and a significantly longer median PFS in the penpulimab arm versus the placebo arm (9.63 versus 7.00 months; hazard ratio 0.45, 95% CI: 0.33-0.62, P < 0.0001) was demonstrated in this prespecified interim analysis. The key secondary endpoint was the overall survival (OS). However, the OS data were still immature, and the median OS was not achieved (hazard ratio, 0.94; 95% CI: 0.63-1.40). The occurrence of treatment-related adverse events (grade ≥ 3) was 89.0% and 85.9% in two arms, with the most common being reduced the quantity of neutrophil (56.2% vs. 62.0%), reduced the quantity of white blood cell (54.1% vs. 54.9%), and anemia (45.2% vs. 38.7%). In the penpulimab arm, 6 patients (4.1%) experienced immune-related adverse events (grade ≥ 3). Adding penpulimab to chemotherapy led to a notable enhancement in PFS for the first-line R/M NPC treatment, alongside a safety profile that was both manageable and tolerable. ClinicalTrials.gov identifier NCT04974398.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2

Fig. 2 Progression-free survival in the ITT population. a Kaplan‒Meier plot of BIRC-assessed progression-free survival (PFS). b Forest plot of BIRC-assessed PFS for subgroup analysis. Data cutoff: April 29, 2024. HR hazard ratio, CI confidence interval, EBV Epstein‒Barr virus, ECOG Eastern Cooperative Oncology Group, PD-L1 programmed death-ligand 1. All HRs were computed using the Cox proportional hazards model. *: The subgroup has less than 10 PFS events, and HR was not reported

A

progression-free survival

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
KM Figure1 个面板

Fig. 3

Fig. 3 Overall survival in the ITT population. Kaplan‒Meier estimates of overall survival with penpulimab plus chemotherapy versus placebo plus chemotherapy are shown. NR not reached, NE not estimable

Overall_survival_in_ITT_population

overall survival

Fig. 3 · Panel Overall_survival_in_ITT_population

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Overall_survival_in_ITT_population 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Patient flow (CONSORT flow diagram). Data cutoff: April 29, 2024. ITT, intent-to-treat. * Two patients from the placebo arm were included in the safety population due to receiving penpulimab by mistake. # Three patients who did not receive placebo and two patients who received penpulimab were excluded from the safety population
非 KM Figure